Waitlist for early access
ImmuNovus is open to early adopters only. Signing up lets us notify you if a conversation opens. It does not enroll you in a study or a care program.
Individuals
Catch the immune trajectory before it has a name
Immune disease is usually recognized at diagnosis, which is late. ImmuNovus is exploring how an individual’s immune data could describe change over time, while there is still room to ask a better question of a care team instead of only reacting to a label.
Why this conversation starts before a diagnosis
Many people first hear about their immune system when something already has a name. The research aim is earlier visibility: a clearer picture of what may be changing, so conversations with clinicians can be more specific. That is not a promise of prevention, and it is not a consumer diagnostic.
What early access means
Informational only
Anything we share helps frame questions for a clinician. It is not a medical service, a test result to act on alone, or a substitute for clinical care.
Built to stay inspectable
The same mechanistic layer used in research is meant to keep assumptions visible. AI may help organize data; it does not replace biological rationale or clinical judgment.
What people typically want to understand
Common reasons people join the waitlist. None of these are disease claims or guaranteed reports.
- General immune health over time
- An autoimmune condition already being treated
- Chronic inflammation
- Recurrent infections
- Recovery after illness
Early access waitlist
ImmuNovus is currently open to early adopters only. Sign up to be waitlisted, and we will notify you when you are in.